GLP1-SARCO

Recruiting

GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes

Evaluation of the Relationship Between GLP-1 Receptor Agonist Use and Sarcopenia in Non-Diabetic Obese Individuals: A Prospective Descriptive Study

Lead sponsor

Istanbul Saglik Bilimleri University

Assets

Semaglutide / Tirzepatide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight, Sarcopenia / muscle

Eligibility highlights

•BMI ≥30

Primary endpoint

•SARC-F total score

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07858864

Org study IDKAEWZ026.06.227

Timeline

Milestones

Study start2026-05-30actual

Study first posted2026-10-05actual

Last update posted2026-10-08actual

Primary completion2026-11-30estimated

Study completion2026-11-30estimated

Assets

Investigational agents

Semaglutide Tirzepatide

Who this study enrolls

Obesity / overweightSarcopenia / muscle

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Adults with obesity and no diabetes referred from the Endocrinology and Metabolism and Internal Medicine outpatient clinics to the Diabetes Education Unit and using a GLP-1 RA.

Inclusion criteria

•Age 18 years or older

•Diagnosis of obesity (BMI >30 kg/m²)

•Currently using a GLP-1 RA

•No hearing, speech or cognitive impairment

•Not receiving treatment for major depressive disorder and not using antidepressants

•Verbal consent to participate

Exclusion criteria

•Diagnosis of diabetes

•History of chronic kidney failure, chronic liver disease, decompensated heart failure or malignancy

•Pregnancy or breastfeeding

•Walking impairment

•Not meeting inclusion criteria or unwilling to participate

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Number of participants with a positive SARC-F screening result

Time frame:Baseline and 3 months

event count, event

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Change in SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls) total score

Time frame:Baseline (GLP-1 RA initiation) and 3 months

change from baseline, improvement

Other/protocol endpoint/low confidence

Change in handgrip strength

Time frame:baseline and 3 months.

change from baseline, improvement

Publications (4)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.